{
  "id": 12997196,
  "title": "TRexBio prices IPO at $14 per share, expects $116.7M",
  "url": "https://urgent.news/2026/10/09/trexbio-prices-ipo-at-14-per-share-expects-116-7m",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-09T01:36:29.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/trexbio-prices-ipo-at-14-per-share-expects-1167m-93CH-4940085"
  },
  "original_language": "en",
  "account": "TRex Bio, Inc., a clinical-stage biotechnology company based in South San Francisco, California, priced its initial public offering (IPO) at $14 per share on Wednesday. According to a press release, the company expects to generate approximately $116.7 million in gross proceeds from the sale of 8,333,334 shares of common stock. These shares will be traded on the Nasdaq Global Select Market under the ticker symbol TRXB, beginning today. The offering is set to close on October 13, 2026, provided all customary closing conditions are met.\n\nUnderwriters for the IPO include J.P. Morgan, Evercore ISI, Cantor, and Stifel, with Wedbush PacGrow and Stifel serving as book-running managers. A registration statement for the shares was filed with the U.S. Securities and Exchange Commission on October 8, 2026. TRexBio's primary focus is on tissue regulatory T cell biology, aiming to develop immunoregulatory medicines for autoimmune and inflammatory diseases. The company is currently headquartered in South San Francisco, California.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Retension Pharmaceuticals prices IPO at $12 per share",
        "url": "https://urgent.news/2026/10/09/retension-pharmaceuticals-prices-ipo-at-12-per-share-12997195",
        "published": "2026-10-09T01:40:30.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}